Data completeness
2/8 — Basic
AMIKIN (amikacin sulfate) by Bristol Myers Squibb is mechanism of action amikacin, an aminoglycoside, binds to the prokaryotic ribosome, inhibiting protein synthesis in susceptible bacteria.
Drug data last refreshed 17h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMIKIN (amikacin sulfate) is an aminoglycoside antibiotic administered by injection that binds to bacterial ribosomes to inhibit protein synthesis. It is bactericidal against both Gram-positive and Gram-negative bacteria, making it a broad-spectrum agent for serious infections.
Pre-Launch
Early-stage product in pre-launch phase with limited commercial infrastructure; career growth depends on successful regulatory approval and market penetration strategy.
Mechanism of Action
Mechanism of Action Amikacin, an aminoglycoside, binds to the prokaryotic ribosome, inhibiting protein synthesis in susceptible bacteria. It is bactericidal in vitro against Gram-positive and Gram-negative bacteria.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Bristol Myers Squibb is hiring 2 roles related to this product
Worked on AMIKIN at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.